Compare BioNano Genomics Inc (BNGO) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Omnicom Group Inc. — how do they compare? BioNano Genomics Inc trades at $1.17 (market cap $13.20M), while Omnicom Group Inc. trades at $81.26 (market cap $23.01B). The key difference: Omnicom Group Inc. is far larger — about 1743.2× BioNano Genomics Inc's market cap, and Omnicom Group Inc. pays a 3.96% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | OMC | |
|---|---|---|
Market Cap | $13.20M | $23.01B |
Sector | Health | Media |
52-Week High | $4.92 | $85.80 |
52-Week Low | $1.09 | $67.27 |
Enterprise Value | $15.81M | $30.24B |
Dividend Yield | — | 3.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
Omnicom Group (OMC) trades at $82.55, up 0.76% today, with a bullish technical signal from moving averages. The stock shows mixed earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results due July 28, 2026. Revenue grew to $17.27B in 2025, though net income was negative, and cash flow improved significantly. Recent news highlights partnerships with IBM, Netflix, and NBCUniversal, enhancing its media and advertising solutions.
Outlook is cautiously optimistic with a consensus price target of $105.75, implying 28% upside, but risks include intense competition and thin profit margins. The stock offers value with a P/E of 12.16 and a dividend, yet investors should monitor earnings sustainability and debt levels amid economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
